T cell exhaustion is recognized as a major challenge in the development of immuno-oncology therapies. It is a broad term used to describe the loss of effector function due to chronic antigen exposure, and commonly occurs within the tumor microenvironment, impairing the T cells ability to effectively eradicate cancerous cells.
The development of tumor specific immunotherapies focuses on overcoming this exhausted phenotype of T cells, to allow targeted killing of the tumor.
The key highlights of this webinar are:
Scientist, iQue® Applications Group
Lauren Kelsey is a Scientist in the iQue® applications group, part of the European based BioAnalytics at Sartorius, where she is involved in the research and development of novel applications. Lauren’s efforts are focused on the iQue®3 advanced flow cytometry platform where she has supported a number of the immuno-oncology campaigns, which are used to exemplify how Sartorius technology can be applied to the drug discovery process.
Lauren obtained a degree in Biology at the University of Bath and went on to complete a masters in Regenerative Medicine, where she studied mouse pancreatic and liver development, before joining Sartorius as an Associate Scientist in 2018.